aBOUT THE CONFERENCE oRGANIZERS

Founded in 1907, the American Association for Cancer Research (AACR) is the world’s first and largest scientific organization in the world focused on every aspect of high-quality, innovative cancer research. Its reputation for scientific breadth and excellence attracts the premier researchers in the field. The programs and services of the AACR foster the exchange of knowledge and new ideas among scientists dedicated to cancer research, provide training opportunities for the next generation of cancer researchers, and increase public understanding of cancer.

The mission of the AACR is to prevent and cure cancer through research, education, communication, and collaboration. Through its programs and services, the AACR fosters research in cancer and related biomedical science; accelerates the dissemination of new research findings among scientists and others dedicated to the conquest of cancer; promotes science education and training; and advances the understanding of cancer etiology, prevention, diagnosis, and treatment throughout the world.

The National Cancer Institute (NCI), founded in 1937, is the U.S. Federal Government’s principal agency for cancer research and training. As the nation’s leading federal agency for cancer research, NCI has 30 divisions, offices, and centers that work together to build, maintain, and enhance a cohesive and comprehensive cancer research agenda. Their work ranges from cutting-edge research on cancer causes, treatment, and prevention; to training the next generation of cancer researchers; to funding and supporting the nation’s vast network of scientists and cancer research institutions; to informing and educating the American public and the world about cancer.

The aims of the European Organisation for Research and Treatment of Cancer (EORTC) are to develop, conduct, coordinate, and stimulate translational and clinical research in Europe to improve the management of cancer and related problems by increasing survival but also patient quality of life. Extensive and comprehensive research in this wide field is often beyond the means of individual European hospitals and can be best accomplished through the multidisciplinary multinational efforts of basic scientists and clinicians.

The goal of the EORTC is to improve the standard of cancer treatment through the testing of more effective therapeutic strategies based on drugs, surgery, and/or radiotherapy that are already in use. The EORTC also contributes to the development of new drugs and other innovative approaches in partnership with the pharmaceutical industry. This is accomplished mainly by conducting large, multicenter, prospective, randomized, phase III clinical trials. In this way, the EORTC facilitates the passage of experimental discoveries into state-of-the-art treatments.

ORGANIZING AND SCIENTIFIC COMMITTEES

ORGANIZING COMMITTEE COCHAIRS:

Philip D. Greenberg, Fred Hutchinson Cancer Center, Seattle, Washington
James H. Doroshow, National Cancer Institute, Bethesda, Maryland
Denis A. Lacombe, European Organisation for Research and Treatment of Cancer, Brussels, Belgium

SCIENTIFIC COMMITTEE COCHAIRS:

Timothy A. Yap, The University of Texas MD Anderson Cancer Center, Houston, Texas
Tim F. Greten, National Cancer Institute, Bethesda, Maryland
E.G. Elisabeth de Vries, University Medical Centre Gronigen, Gronigen, Netherlands

SCIENTIFIC COMMITTEE:

Christina M. Annunziata, National Cancer Institute, Bethesda, Maryland
Rosemarie Aurigemma, National Cancer Institute, Bethesda, Maryland
Udai Banerji, The Institute of Cancer Research, The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom
Bristi Basu, Cancer Research UK Cambridge Institute, Cambridge, United Kingdom
Johanna Bendell, Roche, Basel, Switzerland
Alice P. Chen, National Cancer Institute, Bethesda, Maryland
Deborah E. Citrin, National Cancer Institute, Bethesda, Maryland
Giuseppe Curigliano, University of Milano, European Institute of Oncology, Milano, Italy
Ibiayi Dagogo-Jack, Massachusetts General Hospital Cancer Center, Boston, Massachusetts
E.G. Elisabeth de Vries, University Medical Centre Gronigen, Gronigen, Netherlands
James H. Doroshow, National Cancer Institute, Bethesda, Maryland
Elena Garralda, Vall d’Hebron Research Institute, Barcelona, Spain
Ignacio Garrido-Laguna, University of Utah Huntsman Cancer Institute, Salt Lake City, Utah
Adrian L. Gill, Revolution Medicines, Redwood City, California
Lyndsay N. Harris, National Cancer Institute, Bethesda, Maryland
Timothy Heffernan, The University of Texas MD Anderson Cancer Center, Houston, Texas
Thomas Helleday, Karolinska Institutet, Stockholm, Sweden
Matthew D. Hellman, AstraZeneca Oncology, New York, New York
David Hyman, Loxo Oncology at Lilly, Stamford, Connecticut
Seock Ah Im, Seoul National University, Seoul, Korea
S. Percy Ivy, National Cancer Institute, Bethesda, Maryand
Filip Janku, Monte Rosa Therapeutics, Boston, Massachusetts
Patricia M. LoRusso, Yale Cancer Center, New Haven, Connecticut
Jason J. Luke, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania
Ignacio Melero, Clinica Universidad de Navarra, Pamplona, Spain
Gordon B. Mills, OHSU Knight Cancer Institute, Portland, Oregon
Victor Moreno, START Madrid, Madrid, Spain
Jeffrey A. Moscow, National Cancer Institute, Bethesda, Maryland
Natalie Ngoi, National University Cancer Institute Singapore, Singapore, Singapore
Ralph E.  Parchment, NCI Frederick, Frederick, Maryland
Sophie C. Postel-Vinay, Institut Gustave Roussy, Paris, France
Jordi Rodón, The University of Texas MD Anderson Cancer Center, Houston, Texas
Mark Roschewski, National Cancer Institute, Bethesda, Maryland
Eytan Ruppin, National Cancer Institute, Bethesda, Maryland
Kurt A. Schalper, Yale Cancer Center, New Haven, Connecticut
Patrick Schoffski, Catholic University of Leuven, Leuven Cancer Institute, Leuven, Belgium
Alison Schram, Memorial Sloan Kettering Cancer Center, New York, New York
Lesley Seymour, Queens University, Kingston, Ontario, Canada
Geoffrey I. Shapiro, Dana-Farber Cancer Institute, Boston, Massachusetts
Fiona Simpkins, Perelman School of Medicine University of Pennsylvania, Philadelphia, Pennsylvania
Jean-Charles Soria, Amgen Oncology, Thousand Oaks, California
Ramaprasad Srinivasan, National Cancer Institute, Bethesda, Maryland
Stefan N. Symeonides, University of Edinburgh, Edinburgh, Scotland
Beverly A. Teicher, National Cancer Institute, Bethesda, Maryland
Anish Thomas, National Cancer Institute, Bethesda, Maryland
Samra Turajlic, The Franics Crick Institute, London, England
Eric Van Cutsem, University Hospitals Gasthuisberg / Leuven & KULeuven, Leuven, Belgium
Mike Waring, Northern Institute for Cancer Research, Newcastle upon Tyne, England
Brigitte C. Widemann, National Cancer Institute, Bethesda, Maryland
Noboru Yamamoto, National Cancer Center Hospital, Tokyo, Japan